Trials / Unknown
UnknownNCT03940833
Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Asclepius Technology Company Group (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to infuse BCMA CAR-NK 92 cells to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR enables the NK-92 cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BCMA CAR-NK 92 cells | The subject will be observed for any side effects during this time and all the adverse events will be recorded. |
Timeline
- Start date
- 2019-05-01
- Primary completion
- 2021-05-01
- Completion
- 2022-05-01
- First posted
- 2019-05-07
- Last updated
- 2019-05-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03940833. Inclusion in this directory is not an endorsement.